I’m still dumbfounded how this stock is priced f

I’m still dumbfounded how this stock is priced for complete failure. I understand the Paulson financing rounds and some not believing until they see revenue, but the prostate prognostic test is worth the $150M MC alone IMO. I can see them selling this off as it is an outlier product and they have so many other potential uses for leronlimab they need to look at still and they need cash soon, but my hope is that they will license this for an upfront payment and keep a piece of this easy recurring revenue that has potential sales of $750M annually. I have no idea what a realistic royalty is for this type of test, but seems likely that this alone would pay for the $13.5M ProstaGene acquisition with one full year revenues ($13.5M equals 12% market penetration at $3,000 cost per test and 15% royalty).

Additionally, I look forward to the day we get up-listed so we can get some analyst coverage, institutional ownership, more company/leronlimab awareness, less stock manipulation, etc.

Happy St. Paddy’s Day weekend everyone!

Please do your own due diligence. All my posts and comments are not to be considered investment advice.